Exhaustion-associated regulatory regions in CD8+ tumor-infiltrating T cells

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 13, 2017, Pages E2776-E2785

  Mognol, Giuliana P ^a   Spreafico, Roberto ^b   Wong, Victor ^a,e   Scott Browne, James P ^a   Togher, Susan ^a   Hoffmann, Alexander ^b   Hogan, Patrick G ^a   Rao, Anjana ^a,c,d   Trifari, Sara ^a,f  

^a La Jolla Institute   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d San Diego   (United States)

^e RADY CHILDREN'S HOSPITAL   (United States)

^f SORRENTO THERAPEUTICS   (United States)

Author keywords

Anti PD L1; ATAC seq; Checkpoint blockade therapy; Chromatin accessibility; T cell exhaustion

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 1 INHIBITOR; PROTEIN INHIBITOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NR4A; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; NR4A1 PROTEIN, MOUSE; NUCLEAR RECEPTOR NUR77; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATAC SEQUENCING; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CELL COUNT; CELL STIMULATION; CELL STRESS; CHROMATIN; CHROMATIN ACCESSIBILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG TARGETING; GENE EXPRESSION; IMMUNORECEPTOR TYROSINE BASED INHIBITION MOTIF; IN VITRO STUDY; MOUSE; NEOPLASM; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN MOTIF; SEQUENCE ANALYSIS; TUMOR ASSOCIATED LEUKOCYTE; ANIMAL; C57BL MOUSE; GENETICS; HUMAN; IMMUNOLOGY; MALE; REGULATORY SEQUENCE;

ANIMALS; ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; CHROMATIN; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MICE; MICE, INBRED C57BL; NEOPLASMS; NUCLEAR RECEPTOR SUBFAMILY 4, GROUP A, MEMBER 1; REGULATORY SEQUENCES, NUCLEIC ACID;

EID: 85016431802     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1620498114     Document Type: Article

References (68)

1. Wherry EJ, Kurachi M (2015) Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol 15(8):486-499.
2. Brahmer JR, et al. (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366(26):2455-2465.
3. Robert C, et al. (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372(4):320-330.
4. Tumeh PC, et al. (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515(7528):568-571.
5. van Rooij N, et al. (2013) Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol 31(32):e439-e442.
6. Pleasance ED, et al. (2010) A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463(7278):191-196.
7. Larkin J, et al. (2015) Efficacy and safety of Nivolumab in patients with BRAF V600 mutant and BRAF wild-type advanced melanoma: A pooled analysis of 4 clinical trials. JAMA Oncol 1(4):433-440.
8. Hamid O, et al. (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369(2):134-144.
9. Schietinger A, Greenberg PD (2014) Tolerance and exhaustion: Defining mechanisms of T cell dysfunction. Trends Immunol 35(2):51-60.
10. Rao A, Luo C, Hogan PG (1997) Transcription factors of the NFAT family: Regulation and function. Annu Rev Immunol 15:707-747.
11. Hogan PG, Chen L, Nardone J, Rao A (2003) Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev 17(18):2205-2232.
12. Choi S, Schwartz RH (2007) Molecular mechanisms for adaptive tolerance and other T cell anergy models. Semin Immunol 19(3):140-152.
13. Zajac AJ, et al. (1998) Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med 188(12):2205-2213.
14. Ladányi A, et al. (2004) T-cell activation marker expression on tumor-infiltrating lymphocytes as prognostic factor in cutaneous malignant melanoma. Clin Cancer Res 10(2):521-530.
15. Gros A, et al. (2014) PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. J Clin Invest 124(5):2246-2259.
16. Stephen TL, et al. (2014) Transforming growth factor β-mediated suppression of antitumor T cells requires FoxP1 transcription factor expression. Immunity 41(3):427-439.
17. Shin H, et al. (2009) A role for the transcriptional repressor Blimp-1 in CD8(+) T cell exhaustion during chronic viral infection. Immunity 31(2):309-320.
18. Buggert M, et al. (2014) T-bet and Eomes are differentially linked to the exhausted phenotype of CD8+ T cells in HIV infection. PLoS Pathog 10(7):e1004251.
19. Quigley M, et al. (2010) Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF. Nat Med 16(10):1147-1151.
20. Doedens AL, et al. (2013) Hypoxia-inducible factors enhance the effector responses of CD8(+) T cells to persistent antigen. Nat Immunol 14(11):1173-1182.
21. Staron MM, et al. (2014) The transcription factor FoxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8(+) T cells during chronic infection. Immunity 41(5):802-814.
22. Chang JT, Wherry EJ, Goldrath AW (2014) Molecular regulation of effector and memory T cell differentiation. Nat Immunol 15(12):1104-1115.
23. Youngblood B, et al. (2013) Cutting edge: Prolonged exposure to HIV reinforces a poised epigenetic program for PD-1 expression in virus-specific CD8 T cells. J Immunol 191(2):540-544.
24. Bally AP, Austin JW, Boss JM (2016) Genetic and epigenetic regulation of PD-1 expression. J Immunol 196(6):2431-2437.
25. Buenrostro JD, Giresi PG, Zaba LC, Chang HY, Greenleaf WJ (2013) Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNAbinding proteins and nucleosome position. Nat Methods 10(12):1213-1218.
26. Sen DR, et al. (2016) The epigenetic landscape of T cell exhaustion. Science 354(6316): 1165-1169.
27. Pauken KE, et al. (2016) Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science 354(6316):1160-1165.
28. Scott-Browne JP, et al. (2016) Dynamic changes in chromatin accessibility occur in CD8(+) T cells responding to viral infection. Immunity 45(6):1327-1340.
29. Pipkin ME, et al. (2010) Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells. Immunity 32(1):79-90.
30. Thurman RE, et al. (2012) The accessible chromatin landscape of the human genome. Nature 489(7414):75-82.
31. Schietinger A, et al. (2016) Tumor-specific T cell dysfunction is a dynamic antigendriven differentiation program initiated early during tumorigenesis. Immunity 45(2): 389-401.
32. Falo LD, Jr, Kovacsovics-Bankowski M, Thompson K, Rock KL (1995) Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity. Nat Med 1(7):649-653.
33. Schüler T, Blankenstein T (2003) Cutting edge: CD8+ effector T cells reject tumors by direct antigen recognition but indirect action on host cells. J Immunol 170(9): 4427-4431.
34. Gerner MY, Heltemes-Harris LM, Fife BT, Mescher MF (2013) Cutting edge: IL-12 and type I IFN differentially program CD8 T cells for programmed death 1 re-expression levels and tumor control. J Immunol 191(3):1011-1015.
35. Liu X, et al. (2013) Endogenous tumor-reactive CD8(+) T cells are differentiated effector cells expressing high levels of CD11a and PD-1 but are unable to control tumor growth. OncoImmunology 2(6):e23972.
36. Geissler K, et al. (2015) Immune signature of tumor infiltrating immune cells in renal cancer. OncoImmunology 4(1):e985082.
37. Doering TA, et al. (2012) Network analysis reveals centrally connected genes and pathways involved in CD8+ T cell exhaustion versus memory. Immunity 37(6): 1130-1144.
38. Martinez GJ, et al. (2015) The transcription factor NFAT promotes exhaustion of activated CD8+ T cells. Immunity 42(2):265-278.
39. Seumois G, et al. (2014) Epigenomic analysis of primary human T cells reveals enhancers associated with TH2 memory cell differentiation and asthma susceptibility. Nat Immunol 15(8):777-788.
40. Heinz S, et al. (2010) Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol Cell 38(4):576-589.
41. Wei H, et al. (2016) Cutting edge: Foxp1 controls naive CD8+ T cell quiescence by simultaneously repressing key pathways in cellular metabolism and cell cycle progression. J Immunol 196(9):3537-3541.
42. Bevington SL, et al. (2016) Inducible chromatin priming is associated with the establishment of immunological memory in T cells. EMBO J 35(5):515-535.
43. Oestreich KJ, Yoon H, Ahmed R, Boss JM (2008) NFATc1 regulates PD-1 expression upon T cell activation. J Immunol 181(7):4832-4839.
44. Shaw JP, et al. (1988) Identification of a putative regulator of early T cell activation genes. Science 241(4862):202-205.
45. Jain J, et al. (1993) The T-cell transcription factor NFATp is a substrate for calcineurin and interacts with Fos and Jun. Nature 365(6444):352-355.
46. Kurachi M, et al. (2014) The transcription factor BATF operates as an essential differentiation checkpoint in early effector CD8+ T cells. Nat Immunol 15(4):373-383.
47. Rengarajan J, et al. (2000) Sequential involvement of NFAT and Egr transcription factors in FasL regulation. Immunity 12(3):293-300.
48. Safford M, et al. (2005) Egr-2 and Egr-3 are negative regulators of T cell activation. Nat Immunol 6(5):472-480.
49. Zheng Y, et al. (2013) Egr2-dependent gene expression profiling and ChIP-Seq reveal novel biologic targets in T cell anergy. Mol Immunol 55(3-4):283-291.
50. Austin JW, Lu P, Majumder P, Ahmed R, Boss JM (2014) STAT3, STAT4, NFATc1, and CTCF regulate PD-1 through multiple novel regulatory regions in murine T cells. J Immunol 192(10):4876-4886.
51. Sheppard KA, et al. (2004) PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett 574(1-3):37-41.
52. Xiao Y, et al. (2015) Protein tyrosine phosphatase SHP-1 modulates T cell responses by controlling Cbl-b degradation. J Immunol 195(9):4218-4227.
53. Topalian SL, et al. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443-2454.
54. Hugo W, et al. (2016) Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165(1):35-44.
55. Chowdhury D, Lieberman J (2008) Death by a thousand cuts: Granzyme pathways of programmed cell death. Annu Rev Immunol 26:389-420.
56. Ashton-Rickardt PG (2010) Serine protease inhibitors and cytotoxic T lymphocytes. Immunol Rev 235(1):147-158.
57. Li P, et al. (2012) BATF-JUN is critical for IRF4-mediated transcription in T cells. Nature 490(7421):543-546.
58. Glasmacher E, et al. (2012) A genomic regulatory element that directs assembly and function of immune-specific AP-1-IRF complexes. Science 338(6109):975-980.
59. Macián F, García-Rodríguez C, Rao A (2000) Gene expression elicited by NFAT in the presence or absence of cooperative recruitment of Fos and Jun. EMBO J 19(17): 4783-4795.
60. Speiser DE, et al. (2014) T cell differentiation in chronic infection and cancer: Functional adaptation or exhaustion? Nat Rev Immunol 14(11):768-774.
61. Moran AE, et al. (2011) T cell receptor signal strength in Treg and iNKT cell development demonstrated by a novel fluorescent reporter mouse. J Exp Med 208(6): 1279-1289.
62. Giordano M, et al. (2015) Molecular profiling of CD8 T cells in autochthonous melanoma identifies Maf as driver of exhaustion. EMBO J 34(15):2042-2058.
63. Tirosh I, et al. (2016) Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352(6282):189-196.
64. Turner SJ, Russ BE (2016) Can T cells be too exhausted to fight back? Science 354(6316):1104-1105.
65. Pircher H, Bürki K, Lang R, Hengartner H, Zinkernagel RM (1989) Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen. Nature 342(6249):559-561.
66. Adey A, et al. (2010) Rapid, low-input, low-bias construction of shotgun fragment libraries by high-density in vitro transposition. Genome Biol 11(12):R119.
67. Arlehamn CL, et al. (2014) Transcriptional profile of tuberculosis antigen-specific T cells reveals novel multifunctional features. J Immunol 193(6):2931-2940.
68. Picelli S, et al. (2014) Full-length RNA-seq from single cells using Smart-seq2. Nat Protoc 9(1):171-181